MedTrace Logo

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

NCT07081087 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-03-25

No results posted yet for this study

Summary

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

Conditions

  • Cytopenia
  • MDS

Interventions

DIAGNOSTIC_TEST

PERIBLOOD-MDS

In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology

Sponsors & Collaborators

  • Weizmann Institute of Science

    lead OTHER

Principal Investigators

  • Liran Shlush · The Weizmann Institute of Science

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07081087 on ClinicalTrials.gov